Multiple advantages of DSAEK include successful outcomes, less risk of graft tears, and alternative options for complex patients with comorbidities. Overall, the procedure offers an aspect of simplicity in that it also has less restrictions for donor age criteria compared with DMEK.
Tocilizumab, a recombinant humanized, antihuman monoclonal antibody, can be effective in improving visual acuity and reducing vitreous haze in patients with noninfectious uveitis, according to a recent study.
JIA-associated uveitis is a challenging inflammatory condition in the pediatric population. Adalimumab was found to be effective and safe in reducing ocular imflammation within 2 months and well tolerated over 12 months in JIA-associated uveitis.
Neovascular age-related macular degeneration (nAMD) is well-known as a heterogeneous disease with variable natural history and variable treatment response, said Carl D. Regillo, MD, FACS. Many patients do well without monthly treatment as noted in HARBOR PRN arms.
Treating neovascular age-related macular degeneration (nAMD) patients with anti-vascular endothelial growth factor (anti-VEGF) ranibizumab (Lucentis, Genentech) on a monthly regimen has produced “great results” in clinical trials, said Prof. Mark C. Gillies, MBBS, PhD. “But what happens after that and what happens in real world practice?”
This has been the year of optical coherence tomography (OCT) angiography, numerous retina specialists said. Commercially available systems are available from Carl Zeiss Meditec, Heidelberg Engineering, and Optovue provide a noninvasive way to image retinal vasculature and confirm clinicians’ diagnoses of abnormalities.
Looking back at 2016, incremental improvements in devices are changing how retina surgeons approach and treat surgeries, said a group of experts. For Charles Wykoff, MD, PhD, two novel improvements may not radically alter surgical approaches today, but will have a long-lasting impact down the road.